Pfizer Issues FY26 Adjusted EPS Guidance of $2.80-$3.00
PFE sits 20% above its 52-week low of $21.97.
Summary
Pfizer has provided its full-year adjusted EPS guidance, projecting a range of $2.80 to $3.00. This is a material financial update for a company of Pfizer's size, offering a direct outlook on its expected profitability. Traders will immediately compare this guidance against current analyst consensus estimates to gauge whether it represents a beat, miss, or in-line performance, which will drive short-term stock movement. This guidance is crucial for updating financial models and investment theses. Investors will now focus on the company's upcoming earnings call or investor presentations for further details and context behind these projections.
At the time of this announcement, PFE was trading at $26.44 on NYSE in the Life Sciences sector, with a market capitalization of approximately $149.6B. The 52-week trading range was $21.97 to $28.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.